Joseph Wheat

Indiana Univ-Purdue Univ At Indianapolis

Attributed

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding mix

By agency

NIH$0 · 4

By mechanism

M01$0 · 4

Top collaborators

No co-investigators on record.

Most similar at Indiana Univ-Purdue Univ At Indianapolis

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject”

Sonia M Thomas · Research Triangle Institute$701,865,642
Tracy L Nolen · Research Triangle Institute$474,487,152
George R Seage · Abt Associates, Inc.$172,422,660
Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
Jeffrey P Krischer · University Of South Florida$155,493,283
Charles A Coltman · Southwest Oncology Group$154,811,913

Research focus

Human SubjectHuman Therapy EvaluationClinical ResearchClinical TrialsAids TherapyHiv InfectionsAntiviral AgentsDrug Screening /EvaluationVirus RnaDelavirdineDisease /Disorder Proneness /RiskDosageAidsEye Disorder ChemotherapyFunctional AbilityGanciclovirHuman Immunodeficiency VirusHuman Immunodeficiency Virus 1IndinavirInflammationPerformanceProtease InhibitorRitonavirSaquinavir

Grant awards (28)

EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0

M01 · FY2002 · RR

CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA$0

M01 · FY2002 · RR

GANCICLOVIR/CIDOFOVIR CMV RETINITIS TRIAL$0

M01 · FY2002 · RR

ACTIVITY OF SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMBINATION$0

M01 · FY2002 · RR

CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA$0

M01 · FY2001 · RR

GANCICLOVIR/CIDOFOVIR CMV RETINITIS TRIAL$0

M01 · FY2001 · RR

ACTIVITY OF SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMBINATION$0

M01 · FY2001 · RR

EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0